Skip to content
sellWeak10b5-1 plan

Kevin Charles Gorman sold $1.2M of NBIX

director at NEUROCRINE BIOSCIENCES INC. 9,613 shares at an average of $120.38, traded May 27, 2025, filed May 29, 2025.

Warning score
20
Value
$1.2M
9,613 shares
Holdings after
514,596
-2% from before
From 52-week low
+40%
low $87.54, close $122.64
From 52-week high
-20%
high $153.29, as of May 27, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $1.2M at market
    +25
  • Share of holdings sold
    Sold 1.8% of holdings
    0
  • Cluster
    No other insider selling within 14 days
    0
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

NBIXOct 9, 2026 · close 142.44
Since filing May 29, 2025: +15.2%SPY +34.1% · excess -19.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000914475-25-000137, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 27, 2025SOpen-market sale
Common Stock10b5-1
-9,613$120.38$1.2M514,596May 29, 2025

Related signals

Other insiders at NEUROCRINE BIOSCIENCES INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
32Weak
NBIXsell 310b5-1
NEUROCRINE BIOSCIENCES INC
Matt Abernethy
Chief Financial Officer
$363k
2,311 shares
-5%
21Weak
NBIXsell 310b5-1
NEUROCRINE BIOSCIENCES INC
David W. Boyer
Chief Corp. Affairs Officer
$130k
826 shares
-9%
10Weak
NBIXsell 310b5-1
NEUROCRINE BIOSCIENCES INC
Eric Benevich
Chief Commercial Officer
$333k
2,154 shares
-3%
29Weak
NBIXsell 310b5-1
NEUROCRINE BIOSCIENCES INC
Leslie Norwalk V
director
$946k
6,190 shares
-50%
16Weak
NBIXsell 510b5-1
NEUROCRINE BIOSCIENCES INC
Darin Lippoldt
Chief Legal Officer
$699k
4,376 shares
-9%
25Weak
NBIXsell 510b5-1
NEUROCRINE BIOSCIENCES INC
Gary A Lyons
director
$2.3M
15,000 shares
-11%
24Weak
NBIXsell 410b5-1
NEUROCRINE BIOSCIENCES INC
Eric Benevich
Chief Commercial Officer
$906k
5,970 shares
-12%
40Moderate
NBIXsell 410b5-1
NEUROCRINE BIOSCIENCES INC
George J Morrow
director
$2.2M
15,000 shares
-68%
23Weak
NBIXsell 210b5-1
NEUROCRINE BIOSCIENCES INC
William H Rastetter
director
$2.7M
18,000 shares
-31%
4Weak
NBIXsell 210b5-1
NEUROCRINE BIOSCIENCES INC
Kyle Gano
Chief Executive Officer
$43k
300 shares
-0%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Kevin Charles Gorman sold $1.2M of NBIX | InsiderTell